Leo Raffi Doumanian, MD

Associate Professor of Clinical Urology

Director, USC Institute of Urology - Verdugo Hills Hospital (VHH) of USC

Image of Leo Raffi Doumanian, MD
Is this your profile? Click to edit


Dr. Doumanian is fellowship trained in urologic trauma and genitourinary reconstruction. He joined USC after five years as Director of Genitourinary Trauma and Reconstruction at Temple University Hospital in Philadelphia. Dr. Doumanian specializes in complex surgical management of traumatic, iatrogenic and radiation-induced genitourinary injuries and congenital and acquired diseases of the lower urinary tract and male genitalia. His particular interests include reconstruction of pelvic fracture urethral distraction defects (PFUDD), urethral strictures, penile curvatures and rectourethral fistulae. Additional focus includes corrective surgery for concealed/buried penis, genital lichen sclerosus and Fournier’s gangrene. Dr. Doumanian also has extensive experience treating male incontinence, erectile dysfunction, urinary diversions and neurogenic voiding dysfunction. Over the years, he has acquired unique surgical skills practiced by few urologists. These include skin, lingual and buccal grafts, and advanced muscle and tissue flap transfers. Dr. Doumanian feels these innovative graft and flap techniques improve success, increase patient satisfaction and enhance cosmetic outcomes in genitourinary reconstructive repair. His current research interests include developing standardized protocols to follow post-urethroplasty patients and ascertaining whether racial disparities exist in treatment of urethral stricture disease. Dr. Doumanian has been designated a reconstructive expert and educator by International Volunteers of Urology (IVU). In successful charity campaigns in Mozambique, Kenya and Rwanda, he partnered with local surgeons, residents and medical students for operative instruction in genitourinary reconstruction. His long-term philanthropic goals include recruitment and funding for USC resident participation in IVU.


  • Aquablation in Patients on Antithrombotics: Assessment of Safety, Postoperative Bleeding Rates and Clinical Outcomes Urology. 2023 Nov; 181:112-118. . View in PubMed
  • Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results J Urol. 2023 07; 210(1):143-153. . View in PubMed
  • BJUI Compass. 2022 Mar; 3(2):130-138. . View in PubMed
  • Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH Can J Urol. 2022 02; 29(1):10960-10968. . View in PubMed
  • Outcomes of Alternative Reservoir Placement in the Lateral Retroperitoneum During Inflatable Penile Prosthesis Placement Urology. 2021 06; 152:35-41. . View in PubMed
  • Urethral complications after gender reassignment surgery: a systematic review Int J Impot Res. 2020 Dec; 33(8):793-800. . View in PubMed
  • Editorial Comment J Urol. 2020 12; 204(6):1347. . View in PubMed
  • Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results Can J Urol. 2020 04; 27(2):10147-10153. . View in PubMed
  • Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial Can J Urol. 2020 02; 27(1):10072-10079. . View in PubMed
  • Predictors of Device-related Complications After Exchange of the Pressure-regulating Balloon in Men With an Artificial Urinary Sphincter Urology. 2020 Jan; 135:154-158. . View in PubMed
  • Delayed Presentation of Urethro-Cavernosal Fistula After Urotrauma Urology. 2019 Sep; 131:e7-e8. . View in PubMed
  • Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results Urology. 2019 Jul; 129:1-7. . View in PubMed
  • Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial BJU Int. 2019 08; 124(2):321-328. . View in PubMed
  • Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained Adv Ther. 2019 06; 36(6):1326-1336. . View in PubMed
  • Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial BJU Int. 2019 04; 123(4):651-660. . View in PubMed
  • 5-cm urethral cuff at higher risk? Neurourol Urodyn. 2019 01; 38(1):187-192.. View in PubMed
  • WATER II (80-150 mL) procedural outcomes BJU Int. 2019 01; 123(1):106-112. . View in PubMed
  • Robotic Management of Rectourethral Fistulas After Focal Treatment for Prostate Cancer Urology. 2018 Aug; 118:241. . View in PubMed
  • Three-Piece Inflatable Penile Prosthesis Placement Following Pelvic Radiation: Technical Considerations and Contemporary Outcomes J Sex Med. 2018 07; 15(7):1049-1054. . View in PubMed
  • Surviving Fournier’s gangrene: Multivariable analysis and a novel scoring system to predict length of stay J Plast Reconstr Aesthet Surg. 2018 05; 71(5):712-718. . View in PubMed
  • WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia J Urol. 2018 05; 199(5):1252-1261. . View in PubMed
  • Single-surgeon experience with robot-assisted ureteroneocystostomy for distal ureteral pathologies in adults Korean J Urol. 2013 Aug; 54(8):516-21. . View in PubMed
  • Gunshot wounds to the scrotum: a large single-institutional 20-year experience BJU Int. 2012 Jun; 109(11):1704-7. . View in PubMed
  • Adult urethral stricture disease after childhood hypospadias repair Adv Urol. 2008; 150315. . View in PubMed
  • The extended use of deflux (dextranomer/hyaluronic acid) in pediatric urology Curr Urol Rep. 2006 Mar; 7(2):143-8. . View in PubMed
  • M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transductionII. Denervated rat bladder. J Pharmacol Exp Ther. 2006 Feb; 316(2):875-80. . View in PubMed